Summary Comments
- Most frequently detected viruses in November (all age groups):
- Rhino/Enterovirus: 28.1%
- Rhinovirus: 21.7%
- SARS-CoV-2: 8.69%
- Epidemiological Week 1–48:
- SARS-CoV-2: Increased from 7% (week 44) to 9.6% (week 48)
- Influenza A & B: Remained low:
- Influenza A: 2.3% in week 48
- Influenza B: 0.4% in week 48
- RSV: 1.1% positivity in week 48
Respiratory Viral Multiplex PCR and SARS-CoV-2 PCR: All Age Groups
October 2024:
- Rhino/Enterovirus: 28.2%
- Rhinovirus: 23.1%
- SARS-CoV-2: 7.5%
- Parainfluenza 1–4: 10.4%
- Adenovirus: 3.1%
- Influenza A: 2%
- Influenza B: 3.1%
- RSV: 1.2%
- Metapneumovirus: 6.5%
November 2024:
- Rhino/Enterovirus: 28.1%
- Rhinovirus: 21.7%
- SARS-CoV-2: 8.69%
- Parainfluenza 1–4: 10.1%
- Adenovirus: 2.9%
- Influenza A: 2.3%
- Influenza B: 0.4%
- RSV: 0.6%
- Metapneumovirus: 5.5%
Atypical Bacterial Pathogens (Weeks 1–48)
Detected Pathogens:
- B. pertussis, M. pneumoniae, C. pneumoniae
- 2 cases of Legionella pneumophila in November
Age Distribution:
Bordetella pertussis:
- 0–6 months: 17%
- 6–12 months: 7%
- 1–5 years: 28%
- 6–12 years: 20%
- 13–18 years: 4%
- 19–64 years: 17%
65 years: 7%
Mycoplasma pneumoniae:
- 0–6 months: 2%
- 6–12 months: 5%
- 1–5 years: 27%
- 6–12 years: 28%
- 13–18 years: 8%
- 19–64 years: 26%
65 years: 4%
Chlamydia pneumoniae:
- 0–6 months: 1%
- 6–12 months: 3%
- 1–5 years: 45%
- 6–12 years: 28%
- 13–18 years: 3%
- 19–64 years: 14%
65 years: 2%
Paediatric Respiratory Viral Multiplex PCR Data (Ages 0–12)
<1 Year Age Group
October 2024:
- Rhino/Enterovirus: 42.1%
- Rhinovirus: 35.0%
- Parainfluenza 1–4: 14.0%
- Adenovirus: 10.8%
- SARS-CoV-2: 11.3%
- RSV: 3.4%
- Influenza A: 4.0%
- Influenza B: 0.3%
- Enterovirus: 6.2%
November 2024:
- Rhino/Enterovirus: 41.3%
- Rhinovirus: 33.8%
- Parainfluenza 1–4: 12.1%
- Adenovirus: 10.8%
- SARS-CoV-2: 17.7%
- RSV: 2.0%
- Influenza A: 3.7%
- Influenza B: 0.2%
- Enterovirus: 6.5%
1–5 Year Age Group
October 2024:
- Rhino/Enterovirus: 48.6%
- Rhinovirus: 35.1%
- Enterovirus: 7.8%
- Adenovirus: 13.4%
- SARS-CoV-2: 19.2%
- Influenza A: 4.5%
- Influenza B: 4.8%
- Parainfluenza 1–4: 7.8%
November 2024:
- Rhino/Enterovirus: 51.6%
- Rhinovirus: 35.8%
- Enterovirus: 16.6%
- Adenovirus: 18%
- SARS-CoV-2: 10.7%
- Influenza A: 4.3%
- Influenza B: 4.7%
- Parainfluenza 1–4: 7.8%
6–12 Year Age Group
October 2024:
- Rhino/Enterovirus: 40.4%
- Rhinovirus: 36.1%
- SARS-CoV-2: 2.9%
- Parainfluenza 1–4: 3.6%
- Adenovirus: 7.0%
- Influenza A: 0.8%
- Influenza B: 3.1%
- RSV: 0.7%
November 2024:
- Rhino/Enterovirus: 42.8%
- Rhinovirus: 37.7%
- SARS-CoV-2: 8.1%
- Parainfluenza 1–4: 2.6%
- Adenovirus: 7.8%
- Influenza A: 1.1%
- Influenza B: 0%
- RSV: 0.2%
Age-Specific Highlights (November 2024)
- <1 year:
- Rhino/Enterovirus (41.3%)
- Rhinovirus (33.8%)
- SARS-CoV-2 (17.7%)
- 1–5 years:
- Rhino/Enterovirus (51.6%)
- Rhinovirus (35.8%)
- Enterovirus (16.6%)
- Adenovirus (18%)
- 6–12 years:
- Rhino/Enterovirus (42.8%)
- Rhinovirus (37.7%)
- Adenovirus (7.8%)
Continue Reading